Hepatitis B Treatment Market Research Report - Forecast till 2027

Hepatitis B Treatment Market Research Report, By Type (Acute and Chronic), Treatment (Immune Modulator Drugs, Antiviral Drugs, Vaccine, and Surgery (Liver Transplant)), and Distribution Channel (Hospital & Retail Pharmacies)- Forecast till 2027

ID: MRFR/HC/6347-HCR | February 2021 | Region: Global | 110 pages

Hepatitis B Treatment Market Scenario


The hepatitis B treatment market is expected to register an approximate CAGR of 5.3% during the forecast period, i.e., from 2018 to 2024.


Hepatitis is a viral infection caused by Hepatitis A, B or C virus. The infection results to cause liver infection or inflammation and many times leading to liver damage.


Hepatitis B virus spreads through coming in contact with infected blood, drinking contaminated water, and using infected needles or syringes.  The person suffering from Hepatitis B faces various symptoms such as poor appetite, weakness, jaundice, dark-colored urine, itching on skin, swelling on legs, weight loss, drowsiness and many more. According to the World Health Organization 2018 fact sheet, it was estimated that 257 million people across the world have lived with hepatitis B infection and also mentioned that around 887,000 number of people died from hepatitis B in 2015. Thus, the increasing prevalence of Hepatitis B across the world boosts market growth.


However, the factors such as side effects associated with treatment and medications hinder the market growth.

Hepatitis B Treatment Market Segmentation


The hepatitis B treatment market is segmented on the basis of type, treatment, distribution channel, and region.


Based on type, the market is segmented into acute and chronic. On the basis of treatment, the hepatitis B treatment market is segmented into immune modulator drugs, antiviral drugs, vaccine, and surgery  (liver transplant). The immune modulator drugs are further sub-segmented into pegylated interferon and interferon alpha. The antiviral drugs are sub-segmented into tenofovir disoproxil, entecavir, telbivudine, lamivudine, and others. By distribution channel, the market is segmented into hospital & retail pharmacies and online pharmacies.


Based on region, the market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.


Hepatitis B Treatment Market Key players


Some of the key players in the hepatitis B treatment market are Accord Healthcare Inc., Apotex Corp., Arbutus Biopharma, Arrowhead Pharma, Aurobindo Pharma Limited, Bristol-Myers Squibb Company, Gilead Sciences, Inc., GlaxoSmithKline, Lupin Pharmaceuticals, Inc., Merck & Co., Inc., Par Pharmaceutical, Inc., Teva Pharmaceuticals, Zydus Pharmaceuticals, and Others.


Hepatitis B Treatment Regional Market Summary

Global Hepatitis B Treatment Market Share (%), by Region, 2017


Hepatitis B Treatment Market


Sources: Centers for Disease Control and Prevention, GOV.UK, Society of Cardiovascular Computed Tomography, Indian Brand Equity Foundation, Annual Reports, Press Release, White Paper, And Company Presentation


The Americas dominates the global market for hepatitis B treatment owing to the increasing bacterial infection, development in the clinical practices, and availability and access of best treatments for viral infection in this region.


Moreover, high healthcare expenditure within the Americas boosts the regional market. According to the National Vaccine Information Center, there were 3,370 acute cases of hepatitis B in the US in 2015. Following similar trends, Europe stood second in the global hepatitis B treatment market. On a regional basis, the European market is segmented into Western Europe and Eastern Europe. Europe is estimated to lead the market due to the presence of advanced medical facilities and rising viral infection among the population contributes to increasing the new cases of hepatitis B among the population. According to the World Health Organization data sheet, hepatitis B and C affects a large number of people in the European region. It also, stats that globally, 1.5 million people die every year because of hepatitis B virus. The increasing incidences of hepatitis B in Europe boost market growth.


Asia Pacific is estimated to be the fastest growing region for the hepatitis B treatment market in 2017. A rapidly growing medical diagnostic sector, growing prevalence of bacterial infection and a large number of patients suffering from HIV infection support market growth.


On the other hand, the Middle East and Africa hold the least share in the hepatitis B treatment market owing to stringent government policies, presence of poor economies, lack of awareness, and low healthcare expenditure within the region.
Hepatitis B Treatment Market, by Type


  • Acute

  • Chronic


Hepatitis B Treatment Market, by Treatment


  • Immune Modulator Drugs

    • Pegylated Interferon

    • Interferon Alpha





  • Antiviral Drugs

    • Tenofovir disoproxil

    • Entecavir

    • Telbivudine

    • Lamivudine

    • Others





  • Vaccine

  • Surgery (Liver Transplant)


Hepatitis B Treatment Market, by Distribution Channel


  • Hospital & Retail Pharmacies

  • Online Pharmacies


Hepatitis B Treatment Market, by Key Players


  • Accord Healthcare Inc.

  • Apotex Corp.

  • Arbutus Biopharma

  • Arrowhead Pharma

  • Aurobindo Pharma Limited

  • Bristol-Myers Squibb Company

  • Gilead Sciences, Inc.

  • GlaxoSmithKline

  • Lupin Pharmaceuticals, Inc.

  • Merck & Co., Inc.

  • Par Pharmaceutical, Inc.

  • Teva Pharmaceuticals

  • Zydus Pharmaceuticals


Intended Audience

  • Pharmaceutical Companies

  • Biotechnological Institutes

  • Government and Private Laboratories

  • Research and Development (R&D) companies

  • Medical Research Laboratories



Report Scope:
Report Attribute/Metric Details
  Market Size   2027: Significant Value
  CAGR   5.3% (2018-2024)
  Base Year   2019
  Forecast Period   2020-2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Type, Treatment, Distribution channel
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Accord Healthcare Inc., Apotex Corp., Arbutus Biopharma, Arrowhead Pharma, Aurobindo Pharma Limited, Bristol-Myers Squibb Company, Gilead Sciences, Inc., GlaxoSmithKline, Lupin Pharmaceuticals, Inc., Merck & Co., Inc., Par Pharmaceutical, Inc., Teva Pharmaceuticals, Zydus Pharmaceuticals, and Others
  Key Market Opportunities   New product launches and R&D Amongst major key Players
  Key Market Drivers

  • Growing geriatric population
  • Increasing the prevalence of viral infection
  • Growing sexually transmitted diseases


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :


    Hepatitis B Treatment Market is expected to exhibit a strong 5.3% CAGR over the forecast period from 2018 to 2024.

    The rising prevalence of hepatitis B is the major driver for the market.

    The risk of side effects from hepatitis B therapeutics is the key restraint on the global hepatitis B treatment market.

    The Americas dominates the global hepatitis B treatment market.

    Leading players in the hepatitis B treatment market include Accord Healthcare, Bristol-Myers Squibb, Apotex, Aurobindo Pharma, and Merck, among others.

    TABLE OF CONTENT

    Chapter 1. Report Prologue

    Chapter 2. Market Introduction

    2.1 Definition

    2.2 Scope of the Study

    2.2.1 Research Objective

    2.2.2 Assumptions

    2.2.3 Limitations

    Chapter 3. Research Methodology

    3.1 Introduction

    3.2 Primary Research

    3.3 Secondary Research

    3.4 Market Size Estimation

    Chapter 4. Market Dynamics

    4.1 Drivers

    4.2 Restraints

    4.3 Opportunities

    4.4 Treatment Trends & Assessment

    Chapter 5. Market Factor Analysis

    5.1 Porter’s Five Forces Analysis

    5.1.1 Bargaining Power of Suppliers

    5.1.2 Bargaining Power of Buyers

    5.1.3 Threat of New Entrants

    5.1.4 Threat of Substitutes

    5.1.5 Intensity of Rivalry

    5.2 Value Chain Analysis

    5.3 Pricing Analysis

    Chapter 6. Global Hepatitis B Treatment Market, by Type

    6.1 Introduction

    6.2 Acute

    6.3 Chronic

    Chapter 7. Global Hepatitis B Treatment Market, by Treatment

    7.1 Introduction

    7.2 Immune Modulator Drugs

    7.2.1 Pegylated Interferon

    7.2.2 Interferon Alpha

    7.3 Antiviral Drugs

    7.3.1 Tenofovir disoproxil

    7.3.2 Entecavir

    7.3.3 Telbivudine

    7.3.4 Lamivudine

    7.3.5 Others

    7.4 Vaccine

    7.5 Surgery (Liver Transplant)

    Chapter 8. Global Hepatitis B Treatment Market, by Distribution Channel

    8.1 Introduction

    8.2 Hospital & Retail Pharmacies

    8.3 Online Pharmacies

    Chapter 9. Global Hepatitis B Treatment Market, by Region

    9.1 Introduction

    9.2 America

    9.2.1 North America

    9.2.1.1 US

    9.2.1.2 Canada

    9.2.2 Latin America

    9.3 Europe

    9.3.1 Western Europe

    9.3.1.1 Germany

    9.3.1.2 France

    9.3.1.3 Italy

    9.3.1.4 Spain

    9.3.1.5 UK

    9.3.1.6 Rest of Western Europe

    9.3.2 Eastern Europe

    9.4 Asia-Pacific

    9.4.1 Japan

    9.4.2 China

    9.4.3 India

    9.4.4 Australia

    9.4.5 Republic of Korea

    9.4.6 Rest of Asia-Pacific

    9.5 Middle East & Africa

    9.5.1 United Arab Emirates

    9.5.2 Saudi Arabia

    9.5.3 Oman

    9.5.4 Kuwait

    9.5.5 Qatar

    9.5.6 Rest of the Middle East & Africa

    Chapter 10. Company Landscape

    10.1 Introduction

    10.2 Market Share Analysis

    10.3 Key Development & Strategies

    10.3.1 Key Developments

    Chapter 11 Company Profiles

    11.1 Accord Healthcare Inc.

    11.1.1 Company Overview

    11.1.2 Type Overview

    11.1.3 Financials

    11.2.4 Key Developments

    11.1.5 SWOT Analysis

    11.2 Apotex Corp.

    11.2.1 Company Overview

    11.2.2 Type Overview

    11.2.3 Financial Overview

    11.2.4 Key Developments

    11.2.5 SWOT Analysis

    11.3 Arbutus Biopharma

    11.3.1 Company Overview

    11.3.2 Type Overview

    11.3.3 Financial Overview

    11.3.4 Key Development

    11.3.5 SWOT Analysis

    11.4 Arrowhead Pharma

    11.4.1 Company Overview

    11.4.2 Type/Business Segment Overview

    11.4.3 Financial Overview

    11.4.4 Key Development

    11.4.5 SWOT Analysis

    11.5 Aurobindo Pharma Limited

    11.5.1 Company Overview

    11.5.2 Type Overview

    11.5.3 Financial overview

    11.5.4 Key Developments

    11.5.5 SWOT Analysis

    11.6 Bristol-Myers Squibb Company

    11.6.1 Company Overview

    11.6.2 Type Overview

    11.6.3 Financial Overview

    11.6.4 Key Developments

    11.6.5 SWOT Analysis

    11.7 Gilead Sciences, Inc.

    11.7.1 Overview

    11.7.2 Type Overview

    11.7.3 Financials

    11.7.4 Key Developments

    11.7.5 SWOT Analysis

    11.8 GlaxoSmithKline

    11.8.1 Overview

    11.8.2 Type Overview

    11.8.3 Financials

    11.8.4 Key Developments

    11.8.5 SWOT Analysis

    11.9 Lupin Pharmaceuticals, Inc.

    11.9.1 Overview

    11.9.2 Type Overview

    11.9.3 Financials

    11.9.4 Key Developments

    11.9.5 SWOT Analysis

    11.10 Merck & Co., Inc.

    11.10.1 Overview

    11.10.2 Type Overview

    11.10.3 Financials

    11.10.4 Key Developments

    11.10.5 SWOT Analysis

    11.11 Par Pharmaceutical, Inc.

    11.11.1 Overview

    11.11.2 Type Overview

    11.11.3 Financials

    11.11.4 Key Developments

    11.11.5 SWOT Analysis

    11.12 Teva Pharmaceuticals

    11.12.1 Overview

    11.12.2 Type Overview

    11.12.3 Financials

    11.12.4 Key Developments

    11.12.5 SWOT Analysis

    11.13 Zydus Pharmaceuticals

    11.13.1 Overview

    11.13.2 Type Overview

    11.13.3 Financials

    11.13.4 Key Developments

    11.13.5 SWOT Analysis

    11.14 Others

    Chapter 12 Appendix

    LIST OF TABLES

    Table 1 Global Hepatitis B Treatment Market Industry Synopsis, 2020–2027

    Table 2 Global Hepatitis B Treatment Market Estimates & Forecast, 2020–2027, (USD Million)

    Table 3 Global Hepatitis B Treatment Market, by Region, 2020–2027, (USD Million)

    Table 4 Global Hepatitis B Treatment Market, by Type, 2020–2027, (USD Million)

    Table 5 Global Hepatitis B Treatment Market, by Treatment, 2020–2027, (USD Million)

    Table 6 Global Hepatitis B Treatment Market, by Distribution Channel, 2020–2027, (USD Million)

    Table 7 North America: Hepatitis B Treatment Market, by Type, 2020–2027, (USD Million)

    Table 8 North America: Hepatitis B Treatment Market, by Treatment, 2020–2027, (USD Million)

    Table 9 North America: Hepatitis B Treatment Market, by Distribution Channel, 2020–2027, (USD Million)

    Table 10 US: Hepatitis B Treatment Market, by Type, 2020–2027, (USD Million)

    Table 11 US: Hepatitis B Treatment Market, by Treatment, 2020–2027, (USD Million)

    Table 12 US: Hepatitis B Treatment Market, by Distribution Channel, 2020–2027, (USD Million)

    Table 13 Canada: Hepatitis B Treatment Market, by Type, 2020–2027, (USD Million)

    Table 14 Canada: Hepatitis B Treatment Market, by Treatment, 2020–2027, (USD Million)

    Table 15 Canada: Hepatitis B Treatment Market, by Distribution Channel, 2020–2027, (USD Million)

    Table 16 Latin America: Hepatitis B Treatment Market, by Type, 2020–2027, (USD Million)

    Table 17 Latin America: Hepatitis B Treatment Market, by Treatment, 2020–2027, (USD Million)

    Table 18 Latin America: Hepatitis B Treatment Market, by Distribution Channel, 2020–2027, (USD Million)

    Table 19 Europe: Hepatitis B Treatment Market, Type, 2020–2027, (USD Million)

    Table 20 Europe: Hepatitis B Treatment Market, by Treatment, 2020–2027, (USD Million)

    Table 21 Europe: Hepatitis B Treatment Market, by Distribution Channel, 2020–2027, (USD Million)

    Table 22 Western Europe: Hepatitis B Treatment Market, by Type, 2020–2027, (USD Million)

    Table 23 Western Europe: Hepatitis B Treatment Market, by Treatment, 2020–2027, (USD Million)

    Table 24 Western Europe: Hepatitis B Treatment Market, by Distribution Channel, 2020–2027, (USD Million)

    Table 25 Eastern Europe: Hepatitis B Treatment Market, by Type, 2020–2027, (USD Million)

    Table 26 Eastern Europe: Hepatitis B Treatment Market, by Treatment, 2020–2027, (USD Million)

    Table 27 Eastern Europe: Hepatitis B Treatment Market, by Distribution Channel, 2020–2027, (USD Million)

    Table 28 Asia-Pacific: Hepatitis B Treatment Market, by Type, 2020–2027, (USD Million)

    Table 29 Asia-Pacific: Hepatitis B Treatment Market, by Treatment, 2020–2027, (USD Million)

    Table 30 Asia-Pacific: Hepatitis B Treatment Market, by Distribution Channel, 2020–2027, (USD Million)

    Table 31 Middle East & Africa: Hepatitis B Treatment Market, by Type, 2020–2027, (USD Million)

    Table 32 Middle East & Africa: Hepatitis B Treatment Market, by Treatment, 2020–2027, (USD Million)

    Table 33 Middle East & Africa: Hepatitis B Treatment Market, by Distribution Channel, 2020–2027, (USD Million)

    LIST OF FIGURES

    Figure 1 Research Process

    Figure 2 Segmentation for the Global Hepatitis B Treatment Market

    Figure 3 Market Dynamics for the Global Hepatitis B Treatment Market

    Figure 4 Global Hepatitis B Treatment Market Share, by Type 2020

    Figure 5 Global Hepatitis B Treatment Market Share, by Treatment, 2020

    Figure 6 Global Hepatitis B Treatment Market Share, by Distribution Channel, 2020

    Figure 7 Global Hepatitis B Treatment Market Share, by Region, 2020

    Figure 8 North America Hepatitis B Treatment Market Share, by Country, 2020

    Figure 9 Europe Hepatitis B Treatment Market, by Country, 2020

    Figure 10 Asia-Pacific Hepatitis B Treatment Market Share, by Country, 2020

    Figure 11 Middle East & Africa Hepatitis B Treatment Market Share, by Country, 2020

    Figure 12 Global Hepatitis B Treatment Market: Company Share Analysis, 2020 (%)

    Figure 13 Accord Healthcare Inc.: Key Financials

    Figure 14 Accord Healthcare Inc.: Segmental Revenue

    Figure 15 Accord Healthcare Inc.: Geographical Revenue

    Figure 16 Apotex Corp.: Key Financials

    Figure 17 Apotex Corp.: Segmental Revenue

    Figure 18 Apotex Corp.: Geographical Revenue

    Figure 19 Arbutus Biopharma: Key Financials

    Figure 20 Arbutus Biopharma: Segmental Revenue

    Figure 21 Arbutus Biopharma: Geographical Revenue

    Figure 22 Arrowhead Pharma: Key Financials

    Figure 23 Arrowhead Pharma: Segmental Revenue

    Figure 24 Arrowhead Pharma: Geographical Revenue

    Figure 25 Aurobindo Pharma Limited: Key Financials

    Figure 26 Aurobindo Pharma Limited: Segmental Revenue

    Figure 27 Aurobindo Pharma Limited: Geographical Revenue

    Figure 28 Bristol-Myers Squibb Company: Key Financials

    Figure 29 Bristol-Myers Squibb Company: Segmental Revenue

    Figure 30 Bristol-Myers Squibb Company: Geographical Revenue

    Figure 31 Gilead Sciences, Inc.: Key Financials

    Figure 32 Gilead Sciences, Inc.: Segmental Revenue

    Figure 33 Gilead Sciences, Inc.: Geographical Revenue

    Figure 34 Royal DSM: Key Financials

    Figure 35 Royal DSM: Segmental Revenue

    Figure 36 Royal DSM: Geographical Revenue

    Figure 37 Merck & Co., Inc.: Key Financials

    Figure 38 Merck & Co., Inc.: Segmental Revenue

    Figure 39 Merck & Co., Inc.: Geographical Revenue

    Figure 40 Straumann Holding AG: Key Financials

    Figure 41 Straumann Holding AG: Segmental Revenue

    Figure 42 Straumann Holding AG: Geographical Revenue

    Figure 43 Zimmer Biomet Holdings, Inc.: Key Financials

    Figure 44 Zimmer Biomet Holdings, Inc.: Segmental Revenue

    Figure 45 Zimmer Biomet Holdings, Inc.: Geographical Revenue

    Figure 46 Teva Pharmaceuticals: Key Financials

    Figure 47 Teva Pharmaceuticals: Segmental Revenue

    Figure 48 Teva Pharmaceuticals: Geographical Revenue

    Figure 49 Zydus Pharmaceuticals: Key Financials

    Figure 50 Zydus Pharmaceuticals: Segmental Revenue

    Figure 51 Zydus Pharmaceuticals: Geographical Revenue



    This table of content is tentative and subject to change as the research progresses.

    Please Note:  Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.